- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02715063
Cardiometabolic HIIT-RT Study
October 10, 2018 updated by: Universidad Santo Tomas
High Intensity Interval- vs Resistance or Combined- Training for Improving Cardiometabolic Health in Overweight Adults (Cardiometabolic HIIT-RT Study): Study Protocol for a Factorial Randomised Controlled Trial
Several studies have shown relationship between exercise intensity and improvement cardiometabolic health such as body composition, endothelial function, blood pressure and blood lipids.
It has been suggested that high intensity interval training and also strength or resistance training generate positive effects on metabolic risk factors, nevertheless the comparison between both types of training and their combination has not yet provided conclusive evidence.
Also, it has been shown that dietary restriction has similar or more positive effects that exercise alone and the effect is greater when it is combined with exercise.
For these reasons, it is necessary to clarify which type of training, in combination with a dietary restriction, is more effective to improve cardiometabolic health
Study Overview
Status
Completed
Conditions
Detailed Description
The investigators hypothesized that high intensity interval, resistance training or combined training would result in similar improvements in cardiometabolic health as compared to the usual clinical care in a cohort of sedentary overweight (age 30-50 years old).
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Colombia
- Robinson Ramírez Vélez Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets at least one criteria for metabolic Syndrome (IDF 2006): Central obesity: waist circumference ≥90cm (men) ≥80cm (women); triglycerides ≥ 150mg/dl; HDL-c <40mg/dl (men) <50 (women); Blood pressure ≥130/85mmHg and fasting plasma glucose ≥ 100mg/dL.
- Written informed consent.
- Interested in improving health and fitness.
Exclusion Criteria:
- Systemic infections.
- Weight loss or gain of >10% of body weight in the past 6 months for any reason.
- Currently taking medication that suppresses or stimulates appetite.
- Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.
- Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
- Asthma.
- Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.
- Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).
- Any active use of illegal or illicit drugs.
- Current exerciser (>30 min organized exercise per week).
- Indication of unsuitability of current health for exercise protocol (PARQ).
- Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High Intensity Interval
Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
|
Exercise will be performed at three sessions per week.
All sessions will be supervised by a trained health or exercise professional.
|
|
Active Comparator: Resistance training
Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
|
Exercise will be performed at three sessions per week.
All sessions will be supervised by a trained health or exercise professional.
|
|
Active Comparator: Plus: High Intensity Interval + Resistance Training
Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached.
Exercise will be performed at three sessions per week.
|
Exercise will be performed at three sessions per week.
All sessions will be supervised by a trained health or exercise professional.
|
|
Placebo Comparator: Usual clinical care
This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
|
Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in endothelial function as measured by flow-mediated vasodilation (FMD)
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
FMD will be measured using the guidelines reported by Corretti et al.
The diameter of the brachial artery will be assessed using a high-resolution ultrasound device (Siemens SG-60, USA), equipped with a 7.5 MHz linear array transducer.
|
Baseline and 12 weeks immediately after the interventions ends
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in body Composition as measured by Dual Energy X-ray Absorptiometry
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Changes in abdominal and total adiposity (DEXA), lean tissue mass and bone mass (DEXA) the 12 weeks intervention program
|
Baseline and 12 weeks immediately after the interventions ends
|
|
Body Weight
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Body Mass Index
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
BMI will be calculated as the body weight in kilograms divided by the square of the height in meters.
|
Baseline and 12 weeks immediately after the interventions ends
|
|
Blood Pressure
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in peak uptake of volume of oxygen
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
It will be determined using a maximum treadmill exercise test (Precor TRM 885, Italy) following the modified Balke protocol
|
Baseline and 12 weeks immediately after the interventions ends
|
|
Change from Baseline in muscular fitness
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Muscular fitness (MF) will be assessed using handgrip test (maximum handgrip strength assessment) using a standard adjustable handle analogue handgrip dynamometer T-18 TKK SMEDLY III®
|
Baseline and 12 weeks immediately after the interventions ends
|
|
Change from Baseline in Flexibility using the sit and reach test
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in LDL Cholesterol
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in HDL Cholesterol
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in Triglycerides
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in Glucose
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in Hemoglobin A1c
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in Quality & satisfaction with life by SF Community - short-form survey (SF-12™) Colombian version
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Baseline and 12 weeks immediately after the interventions ends
|
|
|
Change from Baseline in Heart rate variability
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
HRV will be performed according to current recommendations by European Society of Cardiology using an evaluated share-ware
|
Baseline and 12 weeks immediately after the interventions ends
|
|
24-hour dietary recall
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
Dietary data will be collected from participants on 24h of their study enrollment.
Prior to administration of the 24HR, each subject received two-dimensional food models with depiction of foods and serving sizes in order to assist in reporting portion sizes of food intake.
|
Baseline and 12 weeks immediately after the interventions ends
|
|
Aortic pulse wave velocity (PWVao) and augmentation index (AIx)
Time Frame: Baseline and 12 weeks immediately after the interventions ends
|
PWVao and AIx will be measured with oscillometric method using the occlusion technique.
|
Baseline and 12 weeks immediately after the interventions ends
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robinson Ramírez Vélez, Ph.D, Universidad del Rosario
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ramirez-Velez R, Correa-Bautista JE, Gonzalez-Ruiz K, Tordecilla-Sanders A, Garcia-Hermoso A, Schmidt-RioValle J, Gonzalez-Jimenez E. The Role of Body Adiposity Index in Determining Body Fat Percentage in Colombian Adults with Overweight or Obesity. Int J Environ Res Public Health. 2017 Sep 21;14(10):1093. doi: 10.3390/ijerph14101093.
- Ramirez-Velez R, Hernandez A, Castro K, Tordecilla-Sanders A, Gonzalez-Ruiz K, Correa-Bautista JE, Izquierdo M, Garcia-Hermoso A. High Intensity Interval- vs Resistance or Combined- Training for Improving Cardiometabolic Health in Overweight Adults (Cardiometabolic HIIT-RT Study): study protocol for a randomised controlled trial. Trials. 2016 Jun 24;17(1):298. doi: 10.1186/s13063-016-1422-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
March 8, 2016
First Submitted That Met QC Criteria
March 16, 2016
First Posted (Estimate)
March 22, 2016
Study Record Updates
Last Update Posted (Actual)
October 11, 2018
Last Update Submitted That Met QC Criteria
October 10, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-1006-2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Amway (China) R&D CenterNot yet recruitingMetabolic Disorders | Metabolic AbnormalityChina
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
San Diego State UniversityRecruitingBone Disease, MetabolicUnited States
-
Oneness Biotech Co., Ltd.Recruiting
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
Clinical Trials on High Intensity Interval
-
Universidad SurcolombianaMaciste Macias; Gilberto AstaizaRecruiting
-
University of MichiganCompletedGlucose IntoleranceUnited States
-
Kuopio Research Institute of Exercise MedicineKuopio University Hospital; University of Basel; University of Eastern Finland; Social Insurance Institution, FinlandTerminatedUnstable Angina Pectoris | Acute Myocardial Infarction | Recurrent Myocardial InfarctionFinland
-
University of GuelphCompletedPost-Exercise Hypotension | Ambulatory Blood Pressure Monitoring | High-intensity Interval ExerciseCanada
-
Riphah International UniversityCompleted
-
Cairo UniversityKasr El Aini HospitalCompletedDiabetes Mellitus, Type 2Egypt
-
Universidad Santo TomasCompletedMetabolic DiseasesColombia
-
Laboratoire des Adaptations Métaboliques à l'Exercice...CREPS Auvergne Rhône-Alpes / VichyCompletedOverweight | PostmenopausalFrance
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway